THURSDAY, SEPTEMBER 20 TH
|
|
|
- Pamela Davis
- 5 years ago
- Views:
Transcription
1 SCIENTIFIC PROGRAM
2 THURSDAY, SEPTEMBER 20 TH 08:30 08:50 hrs. Welcoming address to the XXIV ALEH CONGRESS 2018 Dr. Fernando Contreras (ALEH President) and Dr. Marlene Perez (Congress President) 08:50 09:00 hrs. Inauguration and welcome speech to the Postgraduate Course: ACHIEVEMENTS AND CHALLENGES OF LATINAMERICAN HEPATOLOGY Dr. Adrián Gadano (Course Director) POSTGRADUATE COURSE: ACHIEVEMENTS AND CHALLENGES OF LATINAMERICAN HEPATOLOGY Director: Dr. Adrián Gadano Secretary: Sebastián Marciano MODULE I BACTERIAL INFECTION IN CIRRHOTIC PATIENTS 09:00 09:20 hrs. Epidemiology of bacterial infections in cirrhotic patients in Latin America Dr. Angelo Matos (Brazil) 09:20 09:40 hrs. Pathophysiology of bacterial infections in cirrhotic patients Dr. Richard Moreau (France) 09:40 10:00 hrs. Diagnosis and treatment of bacterial infections in cirrhotic patients Dr. Agustin Albillos (Spain) 10:00 10:20 hrs. Discussion: Questions & Answers 10:20 10:50 hrs. COFFEE BREAK MODULE II CRITICAL SCENARIOS IN CIRRHOTIC PATIENTS 10:50 11:10 hrs. Treatment for GI bleeding due to portal hypertension in cirrhotic patients Dr. Andrés Cardenas (Spain) 11:10 11:30 hrs. Acute Kidney Injury in cirrhotic patients Dr. Paolo Angeli (Italy) 11:30 11:50 hrs. Acute-on-chronic liver failure: Definition and clinical presentation Dr. Richard Moreau (France) 11:50 12:10 hrs. Discussion: Questions & Answers MODULE III HEPATOCELLULAR CARCINOMA 12:10 12:30 hrs. Hepatocellular carcinoma epidemiology in Latin America Dr. Flair Carrilho (Brazil) 12:30 12:50 hrs. Curative treatment for hepatocellular carcinoma Dr. Federico Piñero (Argentina)
3 12:50 13:10 hrs. Treatment for intermediate and advanced hepatocellular carcinoma Dr. Roberto Leon (Venezuela) 13:10 13:30 hrs. Discussion: Questions & Answers 13:30 14:50 hrs. INDUSTRY SYMPOSIUM HCV (Lunch Box) MODULE IV NON-ALCOHOLIC FATTY LIVER DISEASE 15:00 15:20 hrs. Epidemiology of non-alcoholic fatty liver disease in Latin America Dr. Nahúm Méndez (Mexico) 15:20 15:40 hrs. Pathophysiology of non-alcoholic fatty liver disease Dr. Helena Cortez Pinto (Portugal) 15:40 16:00 hrs. Non-pharmacologic treatment of patients with non-alcoholic fatty liver disease Dr. Marco Arrese (Chile) 16:00 16:20 hrs. Drugs in development for treatment of non-alcoholic fatty liver disease Dr. Aarun Sanyal (USA) 16:20 16:40 Discussion: Questions & Answers 16:40 17:00 hrs. COFFEE BREAK MODULE V VIRAL HEPATITIS 17:00 17:20 hrs. Epidemiology of Hepatitis B in Latin America Dr. Hugo Cheinquer (Brazil) 17:20 17:40 hrs. Staging and current treatment for chronic Hepatitis B Dr. Jose Luis Calleja (Spain) 17:40 18:00 hrs. Epidemiology and diagnosis of Hepatitis E in Latin America Dr. Raymundo Paraná (Brazil) 18:00 18:20 hrs. Acute liver failure Dr. Mario Pessoa (Brazil) 18:20 18:40 Discussion: Questions & Answers FINAL CONFERENCE IN POSTGRADUATE COURSE 18:50 hrs. Current state of Hepatitis C in Latin America. Dr. Marcelo Silva (Argentina) 19:30 20:00 hrs. CONGRESS OPENING CEREMONY
4 FRIDAY, SEPTEMEBER 21 ST 07:00 07:45 hrs. Breakfast with the Expert (25 people max, 25 USD) Room 1: Treatment with DAA in coinfected patients Dr. Richard Sterling (USA) Room 2: Indications for hepatic biopsy in patients with NAFLD Dr. Aarun Sanyal (USA) Room 3: Resistance to DAA. When to test? Dr. Marcelo Silva (Argentina) Room 4: Correct use of albumin in cirrhotic patients Dr. Paolo Angeli (Italy) VIRAL HEPATITIS MODULES - PLENARY SESSION (Room A and B) HEPATITIS C SESSION 08:00-08:20 hrs. Genotype 1 treatment in 2018 Dr. José Luis Calleja (Spain) 08:20-08:40 hrs. Treatments for genotypes 2 and 3 Dr. Michael Fried (USA) 08:40-09:00 hrs. Treatment in special populations (CKD, decompensated patients) Dr. Michael Curry (USA) 09:00-09:20 hrs. Access to treatment: Challenges and strategies in Latin America Dr. David Kersenovich (Mexico) 09:20-09:40 hrs. Case presentation Dr. Juan Carlos Restrepo (Colombia) 09:40-10:00 hrs. Questions & Answers 10:00-10:30 hrs. COFFEE BREAK HEPATITIS B SESSION 10:30 10:50 hrs. New therapeutic options for Hepatitis B in Can we eradicate cccdna? Dr. Anna Lok (USA) 10:50 11:10 hrs. When to stop NUCs treatment? Dr. Adrian Gadano (Argentina)
5 11:10 11:30 hrs. Hepatitis B reactivation Dr. David Bernstein (USA) 11:30 11:50 hrs. Hepatitis Delta. Where do we stand today? Dr. Javier Brahm (Chile) 11:50 12:10 hrs. Case presentation (1 case) Dr. Javier Diaz Ferrer (Peru) 12:10 12:30 hrs. Questions & Answers 12:30 13:30 hrs. ORAL COMMUNICATIONS 13:30 14:30 hrs. INDUSTRY SIMPOSSIUM/LUNCH BREAK SIMULTANEOUS EVENING SESSIONS ALEH-EASL SIMPOSSIUM (Room A) 15:00-15:20 hrs. EASL NAFLD CPGs Dr. Helena Cortez Pinto (Portugal) 15:20-15:40 hrs. Emerging therapies for NAFLD Dr. Helena Cortez Pinto (Portugal) 15:40-16:00 hrs. EASL CPGs on autoimmune and cholestatic liver disease Dr. Tom Hemming Karlsen (Norway) 16:00-16:20 hrs. Trends in liver research: the gut-liver axis Dr. Tom Hemming Karlsen (Norway) 16:20-17:00 hrs. ALEH case presentation ALEH YI Dr. Manuel Mendizabal (Argentina) Case discussion ALEH Chair Dr. Adrian Gadano/EASL ChairALEH Case presentation ALEH YI: Dr. Sebastian Diaz Ramirez (Colombia) Case discussion ALEH Chair: Dr. Alejandra Villamil/EASL Chair 17:00-17:30 hrs. COFFEE BREAK 17:30 18:30 hrs. INDUSTRY SIMPOSSIUM LIVER AND ENDOSCOPY - ALEH-ASGE (Room B) 15:00-15:20 hrs. Pre-anesthesia evaluation sedation of patients with advanced hepatic disease Dr. Rolando Ortega (Colombia) 15:20-15:40 hrs. Treatment of GI bleeding due to esophageal varices Dr. Agustin Albillos (España)
6 15:40-16:00 hrs. Coagulation treatment prior to endoscopy and new anticoagulation medication. What to do? Dr. Arturo Ballestero (Mexico) 16:00-16:20 hrs. Endoscopic management of post-hepatic transplant biliary complication Dr. Andres Cardenas (Spain) 16:20-16:40 hrs. Endoscopic treatment for Primary Sclerosing Cholangitis Dr. Andres Gelrud (Venezuela) 16:40-17:00 hrs. Case presentation. Q&A session Dr. Leon de Metzerville (Costa Rica) 17:00-17:30 hrs. COFFEE BREAK 17:30-18:30 hrs. INDUSTRY SIMPOSSIUM MISCELANEOUS MODULE (Room C) 15:00 15:20 hrs. Hepatitis E: Impact in Latin America Dr. Raymundo Parana (Brazil) 15:20 15:40 hrs. Non-invasive physical methods for hepatic fibrosis Dr. Jose Luis Callejas (Spain) 15:40 16:00 hrs. ACLF: Prognosis and treatment Dr. Paolo Angeli (Italy) 16:00 16:20 hrs. Biological methods for fibrosis determination Dr. Rene Male (Mexico) 16:20 16:40 hrs. Case presentation Dr. Graciela Castro (Mexico) 16:40 17:00 hrs. Questions & Answers 17:00-17:30 hrs. COFFEE BREAK 17:30-18:30 hrs. INDUSTRY SIMPOSSIUM 18:30 hrs. ALEH ASSEMBLY: BOARD, REPRESENTATIVES OF MEMBER COUNTRIES, ALEH PERMANENT COUNCIL
7 SATURDAY, SEPTEMBER 22 ND 07:00 7:45 hrs. BREAKFAST WITH THE EXPERT (Max 25 people, 25 dollars) Room 1: Minimal hepatic encephalopathy: Diagnosis and treatment Dr. Aldo Torre Mexico Room 2: Cardiovascular risk in patients with NASH Dr. Martin Tagle (Peru) Room 3: Hepatitis B treatment in special populations (CKD) Dr. Anna Lok (USA) Room 4: Treatment of acute Hepatitis C in the DAA era Dr. David Berntein (USA) CIRRHOSIS AND ITS COMPLICATIONS PLENARY SESSION (Rooms A and B) 08:00 08:20 hrs. Natural history of hepatic cirrhosis Dr. Guadalupe Garcia-Tsao (Mexico-USA) 08:20 08:40 hrs. Sepsis in the cirrhotic patient Dr. Agustin Albillos (Spain) 08:40 09:00 hrs. Measuring portal pressure in cirrhosis Dr. Guadalupe Garcia Tsao (Mexico) 09:00 09:20 hrs. Management of ascitis and CKD in cirrhotic patients Dr. Paolo Angeli (Italy) 09:20 09:40 hrs. Case presentation Dr. Mirta Castro (Cuba) 09:40 09:50 hrs. Questions & Answers 09:50 10:20 hrs. COFFEE BREAK 10:20 10:40 hrs. Portal thrombosis in cirrhosis: anticoagulation approach Dr. Juan G Abraldes (Canada) 10:40 11:00 hrs. Beta-blockers: indications, contraindications and risks Dr. Richard Moreau (France) 11:00 11:20 hrs. TIPS: indications and complications Dr. Juan G Abraldes (Canada)
8 11:20 11:40 hrs. Management of hepatic encephalopathy Dr. Jorge Luis Poo (Mexico) 11:40 12:00 hrs.. Case presentation Dr. Esteban Ruiz (Costa Rica) 12:00 12:10 hrs. Questions & Answers 12:15 13:15 hrs. ORAL COMMUNICATIONS 13:30 14:30 hrs. INDUSTRY SIMPOSSIUM/LUNCH BREAK ALEH-AASLD RESEARCH WORKSHOP 2018 COURSE DIRECTORS: ANDRÉS CARDENAS AND RAY KIM 08:05-8:10 hrs. Introduction Dr. Ray Kim & Dr. Andres Cardenas 08:10-08:30 hrs. Research in Hepatology- what is hot and what is not! Dr. Marcelo Silva (Argentina) 08:30 08:50 hrs. Liver disease research in children Dr. Ron Sokol (USA) 08:50-09:10 hrs. Principles of Clinical Trials Dr. Anna Lok (USA) 09:10-09:30 hrs. Cohort and case control studies Dr. Ray Kim (USA) 09:30 9:50 hrs. How to set up study databases Dr. Michael Fried (USA) 09:50-10:10 hrs. Q&A 10:10-10:30 hrs. COFFEE BREAK 10:30 10:50 hrs. Ethical and regulatory aspects in clinical research Dr. Michael Fried (USA) 10:50-11:10 hrs. How to write a paper and get published Dr. Guadalupe Garcia-Tsao (Mexico-USA) 11:10 11:30 hrs. Writing a proposal and grant Dr. Anna Lok (USA) 11:30-11:50 hrs. Presentation Skills Dr. Andres Cardenas (Spain)
9 11:50 12:10 hrs. Research training opportunities in North America Dr. Ron Sokol (USA) 12:10 12:30 hrs. Q&A 12:30 13:00 hrs. Lunch 13:00 pm 15:00 pm Lunch with fellows Interaction of all faculty. Poster presentations with feedback on: Design Writing / Style Presentation skills Content / Science Approx Posters in 1 large room with different stations or alternatively 6-8 fellows oral presentations SIMULTANEOUS SESSIONS IN ROOMS A, B, C & D AUTOINMUNE HEPATITIS MODULE (Room A) 15:00 15:20 hrs. Current treatment of autoimmune hepatitis Dr. Alejandra Villamil (Argentina) 15:20 15:40 hrs. Primary Billiary Cholangitis. Therapeutic advances Dr. Tom Hemming Karlsen (Norway) 15:40 16:00 hrs. Pruritus treatment Dr. Richard Sterling (USA) 16:00 16:20 hrs. Overlap syndrome Dr. Tom Hemming Karlsen (Norway) 16:20 16:40 hrs. Case presentation Dr. Enrique Adames (Panama) 16:40 17:00 hrs. Questions & Answers 17:00 17:30 hrs. COFFEE BREAK 17:30 18:30 hrs. INDUSTRY SIMPOSSIUM A-B-C LIVER INFILTRATIVE DISEASES MODULE (Room B) 15:00 15:20 hrs. Wilson s disease: treatment and prognosis Dr. Francisco Hevia (Costa Rica) 15:20 15:40 hrs. Liver disease due to iron deposition Dr. Javier Brahm (Chile)
10 ROUND TABLE DILI 15:20 15:40 hrs. Liver disease due to iron deposition Dr. Javier Brahm (Chile) 15:40 15:55 hrs. How to diagnose DILI? Present and future Dr. Raul J. Andrade (Spain) 15:55 16:15 hrs. What have we learned during the last decade? New drugs & old myths Dr. Raymundo Parana (Brazil) 16:15 16:30 hrs. Accomplishments and progress with the Latin American registry Dr. Nelia Hernandez (Uruguay) 16:30 16:50 hrs. Presentation of 2018 Latin American Guidelines of hepatotoxicity Dr. Fernando Bessone (Argentina) 16:50 17:00 hrs. Questions & Answers 17:00 17:30 hrs. COFFEE BREAK 17:30 18:30 INDUSTRY SIMPOSSIUM LIVER TRANSPLANT MODULE (Room C) 15:00 15:20 hrs. New options for immunosuppression in the transplanted patient Dr. James Trotter (USA) 15:20-15:40 hrs. Indications and evaluation of candidates for liver transplants Dr. George Therapondos (Ochsner Clinic, USA) 15:40 16:00 hrs. Liver transplantation in acute liver failure Dr. Humberto Bohorquez (Ochsner Clinic, USA) 16:00-16:20 hrs. How to grow the donor pool: Asystole, Split, Living Donor Dr. James Trotter (USA) 16:20-16:40 hrs. Case presentation Dr. Juan Suarez (Ecuador) 16:40-17:00 hrs. Questions & Answers session 17:00 17:30 hrs. COFFEE BREAK 17:30 18:30 hrs. INDUSTRY SIMPOSSIUM
11 ALCOHOLIC HEPATITIS AASLD-ALEH (Room D) 15:00 15:20 hrs. What do we know of alcoholic liver disease in Latin America? Dr. Juan Pablo Roblero (Chile) 15:20 15:40 hrs. Treatment of severe alcoholic hepatitis Dr. Ramon Bataller (USA) 15:40 16:00 hrs. Liver transplant in alcoholic liver disease Dr. Michael Curry (USA) 16:00 16:20 hrs. ASH vs non-alcoholic steatohepatitis or both Dr. Arun Sanyal (USA) 16:20 16:40 hrs. Case presentation Dr. Juan Carlos Restrepo (Colombia) 16:40 17:00 hrs. Questions & Answers 17:00 17:30 hrs. COFFEE BREAK 18:30 18:45 hrs. ALEH HEPATOLOGIST LIFETIME ACHIEVEMENT AWARD 18:45 19:00 hrs. ALEH PRESIDENCY HANDOVER CEREMONY 20:30 hrs. CLOSING DINNER SUNDAY, SEPTEMBER 23 RD 08:00-09:00 hrs. INDUSTRY SIMPOSIUM PLENARY SESSION (ROOMS A & B) HEPATOCELLULAR CARCINOMA AND FATTY LIVER DISEASE MODULE HEPATOCELULLAR CARCINOMA 09:00-09:20 hrs. Radiologic diagnosis of hepatocellular carcinoma Dr. Louis Mauricio Morel (Dominican Republic) 09:20-09:40 hrs. Diagnosis and treatment of early stage hepatocellular carcinoma Dr. Christie Perello (Dominican Republic) 09:40-10:00 hrs. Diagnostic and treatment of intermediate-advanced hepatocellular carcinoma Dr. Flair Carihlo (Brazil) 10:00-10:20 hrs. Cholangiocarcinoma Dr. Andres Gelrud (Venezuela).
12 10:20-10:40 hrs. Case presentation Dr. Federico Pineiro (Argentina) 10:40-10:50 hrs. Questions & Answers 10:50-11:10 hrs. COFFEE BREAK FATTY LIVER DISEASE 11:10-11:30 hrs. Epidemiology and natural history of fatty liver disease Dr. Ignacio Aiza (Mexico) 11:30-11:50 hrs. NASH pathogenesis Dr. Milagros Davalos (Peru) 11:50-12:10 hrs. Diagnostic methods in fatty liver disease Dr. Marco Arrese (Chile) 12:10-12:30 hrs. Lifestyle interventions in NASH patients Dr. David Bernstein (USA) 12:30-12:50 hrs. New therapeutic targets Dr. Arun Sanyal (USA) 12:50-13:00 hrs. Questions & Answers 13:00-13:15 hrs. ORAL COMMUNICATION AWARDS CLOSURE
PROGRAMME AT A GLANCE
PROGRAMME AT A GLANCE Hotel Hyatt Andaz Hotel Pullman Date Hall-H1 Hall-H2 Hall-P1 Hall-P2 Hall-P3 Hall-P4 Hall-P5 Hall-P6 Basic science workshop 1 Basic Science Workshop 2 Postgraduate Course - Liver
FRIDAY, MARCH 9 SUNDAY, MARCH
33RD A N N U A L New Treatments in Chronic Liver Disease FRIDAY, MARCH 9 SUNDAY, MARCH 11, 2018 Pre-Conference: Friday, March 9, 2018 Main Conference: Saturday, March 10-11, 2018 Estancia La Jolla Course
Transplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
4th UpDate on Hepatology
4th UpDate on Hepatology Course Bucharest 2017, Romania 6 th - 7 th April 2017 Bucharest - Crowne Plaza Hotel Hepatology 2017 A panoramic view" Liana GHEORGHE Course Directors Ioan SPOREA Anca TRIFAN 4
The Sheila Sherlock Royal Free Hepatology Postgraduate Course Date: 15 th 17 th May 2019 Location: Royal Free Hospital, London, United Kingdom
The Sheila Sherlock Royal Free Hepatology Postgraduate Course 2019 Date: 15 th 17 th May 2019 Location: Royal Free Hospital, London, United Kingdom *Includes histopathology within talk # Includes radiology
15 & 16 January International Conference on the Management of Liver Diseases. Organised by Pr Patrick Marcellin
15 & 16 January 2018 PARIS - Palais des Congrès International Conference on the Management of Liver Diseases Organised by Pr Patrick Marcellin Organising Committee Blaise Kutala, Monelle Muntlak Hôpital
July 5 & 6, 2018, Paris SCIENTIFIC PROGRAM
www.paris-nash.org Dear Colleagues, We are delighted to announce the 4th Paris NASH Meeting to be held on July 5-6 th 2018. This international academic meeting is aimed to do a deep-dive into many aspects
FRIDAY, MARCH 31 SUNDAY, APRIL
32ND A N N U A L New Treatments in Chronic Liver Disease FRIDAY, MARCH 31 SUNDAY, APRIL 2, 2017 Pre-Conference: Friday, March 31, 2017 Main Conference: Saturday, April 1-2, 2017 Estancia La Jolla La Jolla,
Overall Goals and Objectives for Transplant Hepatology EPAs:
Overall Goals and Objectives for Transplant Hepatology EPAs: 1. DIAGNOSTIC LIST During the one-year Advanced Pediatric Transplant Hepatology Program, fellows are expected to develop comprehensive skills
The Role of Liver Societies in the Global Viral Hepatitis Response
The Role of Liver Societies in the Global Viral Hepatitis Response Anna S. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
Version 1.11 of 20/07/2018
Version 1.11 of 20/07/2018 NICE JANUARY 17-19, 2019 6 th International Workshop on Lung Health New approaches to respiratory diseases PRESIDENTS: F. BLASI, G.W. CANONICA CHAIRMEN: S. CENTANNI, J.C. VIRCHOW,
5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition
5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition SIXTH DRAFT OF THE PROGRAM AUGUST 28, 2014 Wednesday, October 5, 2016 08:00-16:30 Post Graduate course (To be developed by the
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
Gastroenterology. Certification Examination Blueprint. Purpose of the exam
Gastroenterology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified gastroenterologist
The Role of Liver Societies in the Global Viral Hepatitis Response
The Role of Liver Societies in the Global Viral Hepatitis Response Anna S. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
Organized by. Scientific comittee
July 11 & 12, 2019 Institut Pasteur Organized by Arun Sanyal Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA Lawrence Serfaty Hôpital Hautepierre Hôpitaux Universitaires de
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
Worldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
34TH. New Treatments in Chronic Liver Disease. MAIN CONFERENCE: MARCH 9 10, 2019 Pre-Conference: March 8, 2019 Estancia La Jolla La Jolla, California
34TH A N N U A L New Treatments in Chronic Liver Disease MAIN CONFERENCE: MARCH 9 10, 2019 Pre-Conference: March 8, 2019 Estancia La Jolla Course Introduction Course Overview This CME conference will review
During the course of the 12 month fellowship, candidates will attend at least one international liver meeting (generally AASLD).
Hepatology and Liver Transplantation fellowship Length: 1 year Number of positions: 2 Type of fellowship: Clinical and Research Fellowship Director: Dr. Deschenes McGill University Health Centre Fellowship
Senior Management Team Meeting Target setting in Latin America
Senior Management Team Meeting Target setting in Latin America October 2006 Nancy Andrade-Castro RST Latin America Geneva/2006 For all enquiries, please contact Nancy Andrade-Castro, Acting Director for
Organized by: Division of Hepatology and Gene Therapy
Organized by: Division of Hepatology and Gene Therapy WELCOME MESSAGE Pamplona, June 2004 Dear colleagues, Welcome to Frontiers 2004! This new edition of Frontiers is an especial one since it coincides
Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
Program Schedule Template Monday, February 23, 2015 Time Topic 7:00 a.m. Registration and Continental Breakfast 7:30 a.m. Welcome and Introductions
Program Schedule Template Monday, February 23, 2015 7:00 a.m. Registration and Continental Breakfast 7:30 a.m. Welcome and Introductions William Sanchez, M.D., Shabana F. Pasha, M.D. and Michael F. Picco,
Lahey Clinic Internal Medicine Residency Program: Curriculum for Gastroenterology
Lahey Clinic Internal Medicine Residency Program: Curriculum for Gastroenterology Faculty representative: David L. Burns, MD, CNSP Resident representative: Tom Castiglione, MD Revision date: March 6, 2006
Autoimmune Hepatitis Events Easl
Autoimmune Hepatitis Events Easl 1 / 6 2 / 6 3 / 6 Autoimmune Hepatitis Events Easl INTRODUCTION. Autoimmune hepatitis is a chronic, inflammatory disease of the liver that is characterized by circulating
A Review of Liver Function Tests. James Gray Gastroenterology Vancouver
A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
SCIENTIFIC PROGRAMME
SCIENTIFIC PROGRAMME Tuesday, May 25 th 2017 08.30-09.30 ORAL PRESENTATIONS (HALL 1) Chairpersons : G. Baltagiannis, E. Vezali 08.30-09.30 Oral Presentations HALL 2) Chairpersons: E. Dimou, O. Giouleme
Hepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
Life After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS
HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS HEPAMAP: A Roadmap For Hepatology Research In Europe: An Overview For Policy Makers Liver diseases are extremely costly
Liver transplant: what is left after the viruses
Riunione Monotematica A.I.S.F. 2016 The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist? Milan 15 th 2016 Liver transplant: what is left after the viruses Stefano Ginanni Corradini
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph
Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,
Hepatology For The Nonhepatologist
Hepatology For The Nonhepatologist Andrew Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Learning Objectives After attending this presentation, learners will be able
INTERNATIONAL WORKSHOP ON MANAGEMENT OF END STAGE LIVER DISEASE DUE TO NASH WASHINGTON DC, USA 6-7 OCTOBER 2016 MEETING PROSPECTUS www.expertmedicalevents.com www.expertmedicalevents.com INTRODUCTION NAFLD
http://www.lactrimsweb.org/ Instituto de Neurología Facultad de Medicina Montevideo Uruguay I LATIN AMERICAN COURSE OF NEUROEPIDEMIOLOGY HOTEL RIU PANAMÁ APRIL 1 7, 2018 Pre-Registration: www.neuroepidemiologia.edu.uy/
MINI PROGRAMME SEE YOU NEXT YEAR IN LONDON APRIL 2020
MINI PROGRAMME WWW.ILC-CONGRESS.EU SEE YOU NEXT YEAR IN LONDON 15-19 APRIL 2020 Registration area Foyer D Membership fast-track, self-registration lanes, help desk, accommodation desk, congress material,
The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist. K V Speeg, MD, PhD UT Health San Antonio
The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist K V Speeg, MD, PhD UT Health San Antonio Objectives Review staging of liver disease Review consequences of end-stage
HCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
EVALUATION REPORT
International Workshop on NASH Biomarkers 2017 5-6 May 2017 Washington, D.C., EVALUATION REPORT www.expertmedicalevents.com/nashbiomarkers EXECUTIVE SUMMARY INTRODUCTION The 2 nd International Workshop
NEURO- GASTRO- ENTEROLOGY & MOTILITY OESO- PHAGUS LOGY. Room A Room B Room C Room E1 Room E2 Room M Room N1 Room N2 Room L8 Room 1.
ONCO ENTERO RADIO & SATURDAY SUNDAY MONDAY TUESDAY WEDNESDAY Saturday, October 15, 2016 Room A Room B Room C Room E1 09:00-10:30 Peptic ulcer : Still important for gastroenterologists 11:00-13:00 Video
EVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
Improving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
A precision medicine approach to comprehensive NAFLD diagnosis via metabolomics-based liquid biopsy
A precision medicine approach to comprehensive NAFLD diagnosis via metabolomics-based liquid biopsy International Workshop on NASH Biomarkers May 5-6 2017, Washington D.C. Pablo Ortiz, MD, PhD (OWL CEO)
LIVER DISEASE WRAP-UP
20th Annual LIVER DISEASE WRAP-UP An Update on Advances in Clinical Hepatology An update on advances in clinical hepatology presented at the 2017 AASLD Meeting for Practicing Internists, Gastroenterologists,
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.
1 ST EUROPEAN. NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT.
1 ST EUROPEAN NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT NEEDS ASSESSMENT NEEDS ASSESSMENT Non-alcoholic fatty liver disease (NAFLD) is an emerging liver disease affecting 25 % of
SCIENCE. Saturday, November 13, Goldwurm Auditorium Mount Sinai School of Medicine New York, NY. Course Directors Douglas T.
SCIENCE in the CITY Saturday, November 13, 2010 Goldwurm Auditorium Mount Sinai School of Medicine New York, NY Course Directors Douglas T. Dieterich, MD, Division of Liver Diseases Director, Continuing
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
Acute Liver Failure. Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018
Acute Liver Failure Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018 Disclosures None Outline Overview of ALF Management of ALF Diagnosis of ALF Treatments and Support
FOCIS goes South: ADVANCES IN TRANSLATIONAL AND CLINICAL IMMUNOLOGY
FOCIS Center of Excellence Millennium Institute on Immunology and Immunotherapy & The Federation of Clinical Immunology Societies, FOCIS WORKSHOP FOCIS goes South: ADVANCES IN TRANSLATIONAL AND CLINICAL
Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
EPNV-Montreux 2018: Preliminary Educational and Scientific Program
EPNV-Montreux 2018: Preliminary Educational and Scientific Program April 25-26, 2018: Pre-Conference Workshops Wednesday (April 25): 09 00 18 00 Thursday (April 26): 08 00 12 00 April 26-28, 2018: Main
ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme July 2016, Valencia, Spain
ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme 14-19 July 2016, Valencia, Spain Co-chairs: Andrés Cervantes, ES - Nicholas Pavlidis, GR - Susana Banerjee, UK Thursday, 14
GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint
GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Gastroenterology MOC exam blueprint Based on feedback from physicians that MOC assessments
Histiocytosis in Argentina Since 1991
Histiocytosis in Argentina Since 1991 AIM To present the experience of a multidisciplinary study group focused on rare and complex histiocytic disorders. Langerhans Cell Histiocytosis (LCH) Disregulation
MEETING PROSPECTUS www.virology-education.com CONTENT Introduction... 3 Workshop description... 4 Background...4 Meeting Objectives...4 Learning Objectives...4 Format...4 Unique Meeting Features...4 Target
Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
LIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.
LIVER CIRRHOSIS William Sanchez, M.D. & Jayant A. Talwalkar, M.D., M.P.H. Advanced Liver Disease Study Group Miles and Shirley Fiterman Center for Digestive Diseases Mayo College of Medicine Rochester,
KIDNEY LIVER MEETS FINAL PROGRAM KIDNEY MEETS LIVER. When the excellence in renal and liver medicine come together. XXXXXXX
XXXXXXX When the excellence in renal and liver medicine come together. 1 COMITATI SCIENTIFIC PROGRAM Organizing Committee Prof. Michel Jadoul Chief Service de Nephrologie Clinique Universitaire Saint-Luc
Gastrointestinal Oncology
2 nd MD ANDERSON INTERNATIONAL MEETING IN Gastrointestinal Oncology CURRENT PRACTICE AND CONTROVERSIES in the Era of Personalized Medicine e Madrid, 13 th -15 th November, 2019 SCIENTIFIC PROGRAM Meeting
Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation
Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation Siwaporn Chainuvati, MD Faculty of Medicine Siriraj Hospital Outline Natural history of esophageal varices Which
ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
Elaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus / Fax
Elaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus 231-727-5575/231-728-4054 Fax » CURABLE» Most common blood borne infection» 75-85% of those exposed will develop chronic infection»
EACS HIV Summer School PRELIMINARY PROGRAMME
EACS HIV Summer School Thursday, August 30, 2018 Monday, September 3, 2018 Montpellier, France This 5-day residential course is designed for clinicians experienced in HIV management who want an update
Hepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
Implementing Standards in Training in Latin America
Implementing Standards in Training in Latin America Prof. Silvio Tatti MD, MSc, Phd, FACOG Immediate Past President IFCPC Full Professor of Gynaecology Chief Division Gynaecology Buenos Aires University
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACLF. See Acute-on-chronic liver failure (ACLF) Acute kidney injury (AKI) in ACLF patients, 967 Acute liver failure (ALF), 957 964 causes
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
Is pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis?
Controversies en Gastroenterology Is pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis? Rolando José Ortega Quiroz, MD, 1 Adalgiza
International Hepatology Ultrasound Course The Atrium, The Royal Free Hospital 1st - 3rd June
International Hepatology Ultrasound Course 2018 The Atrium, The Royal Free Hospital 1st - 3rd June Course run by Supported by Endorsed by Course Sponsors Course Information We are pleased to invite you
The place of bariatric surgery in NASH: can we extend the indications? - No
The place of bariatric surgery in NASH: can we extend the indications? - No Nicolas Goossens Service de Gastroentérologie & Hépatologie Hôpitaux Universitaires de Genève Genève, Suisse How to extend the
Variceal bleeding. Mainz,
Variceal bleeding Mainz, 21.09.2008 Risk of complications 5 years 10 years Ascites 10 % 25 % HCC 10 % 25 % Bleeding < 5 % 5-10 % Enceph. < 5 % < 5 % Typical situation : Mortality 10 % to 40 % Sequence
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
LIVER CANCER: NOVEL ADVANCEMENTS IN 2018
MOUNT SINAI LIVER CANCER PROGRAM 13 TH ANNIVERSARY NOVEL ADVANCEMENTS IN 2018 FRIDAY, DECEMBER 14, 2018 Hatch Auditorium 1468 Madison Avenue, 2 nd floor New York, NY Program Director JOSEP M. LLOVET, MD,
Current Status in Latin America
WHO International Consultation 15 to 17 October 2014 Munich, Germany JUSTIFICATION OF THE USE OF CT FOR INDIVIDUAL HEALTH ASSESSMENT OF ASYMPTOMATIC PEOPLE Current Status in Latin America Gloria Soto Giordani
Joint Banff/CST Program Committee Co-chairs: Dr. Alexandre Loupy and Dr. Prosanto Chaudhury. Joint Banff/CST Finance Committee
2015 Banff/CST Meeting Organizing Corporation ( 2015 MOC ) Co-Directors: Dr. John Gill, Dr. Michael Mengel Members: Anthony Jevnikar, David Rush, Denis Glotz, Kim Solez, Marcelo Cantarovich, Mark Haas,
Clinical Trials & Endpoints in NASH Cirrhosis
Clinical Trials & Endpoints in NASH Cirrhosis April 25, 2018 Peter G. Traber, MD CEO & CMO, Galectin Therapeutics 2018 Galectin Therapeutics NASDAQ: GALT For more information, see galectintherapeutics.com
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
Target audience. Jorge Correale Department of Neurology Raúl Carrea Institute for Neurological Research (FLENI) Buenos Aires, Argentina
EXCEMED Blended Education Immune and clinical profiling in multiple sclerosis: laying groundwork for advanced approaches to treatment Live intervention in PRELIMINARY PROGRAMME Immune and clinical profiling
Hepatitis B and C in the Spotlight: A public health response in the Americas. Key Messages
2017 highlights Hepatitis B and C in the Spotlight: A public health response in the Americas Key Messages Regarding the national structures developed to support the response to the viral hepatitis epidemics,
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
XXVI CINP CONGRESS. mood disorders: The application. Gerhard Heinze M.D.
XXVI CINP CONGRESS CINP Task Force: Antidepressants and mood disorders: The application The impact of antidepressants and the treatment of depression in Latin America Gerhard Heinze M.D. Life expectancy
CIRROSI E IPERTENSIONE PORTALE NELLA DONNA
Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di
Liver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York
Liver Pathology and the Clinician in 2015: At the Crossroads Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York DISCLOSURES Consultant for: Salix Merck Gilead BMS Synageva Research funding:
WHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH?
WHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH? Helena Cortez-Pinto Laboratório de Nutrição, FML, Serviço de Gastrenterologia, Hospital St Maria, Lisboa, Portugal EASL Governing Board:
Programme. TTS New Key Opinion Leader Meeting Thursday September 21 st Arrivals and Dinner at the Hotel. Friday September 22 nd
TTS New Key Opinion Leader Meeting 2006 Programme Thursday September 21 st Arrivals and Dinner at the Hotel After dinner approx 9.00pm Pioneers in Transplantation Professor Josep Ma Caralps Heart transplantation
Worldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
INTERNATIONAL SYMPOSIUM
INTERNATIONAL SYMPOSIUM ACTIVE BRAINS FOR ALL: Exercise, cognition and mental health. GRANADA (SPAIN) 12 nd June 2017 PROGRAM INTRODUCTION Brain research is considered one of the key challenges of the
Learning Objectives. After attending this presentation, participants will be able to:
Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation
UMHS-PUHSC JOINT INSTITUTE
Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC Lai WEI and Anna LOK W Zhang,
LOCAL AND INTERNATIONAL COMMITTEES
LOCAL AND INTERNATIONAL COMMITTEES Chairs: Eduardo Richardet and Norma Pilnik International Chair: Christian Rolfo (Belgium) Educational & IASLC School of Medicine Chair: Luis E. Raez (USA) Scientific
Ontario s Adult Referral and Listing Criteria for Liver Transplantation
Ontario s Adult Referral and Listing Criteria for Liver Transplantation Version 3.0 Trillium Gift of Life Network Ontario s Adult Referral & Listing Criteria for Liver Transplantation PATIENT REFERRAL
Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice
Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice Authors: Mafalda Sousa, Sónia Fernandes, Luísa Proença, Ana Paula Silva, Sónia Leite, Joana Silva, Ana